NCT00803998

Brief Summary

The Ocular Hypertension Treatment Study is a multi-center clinical trial sponsored by the National Eye Institute, designed to determine the efficacy and safety of topically administered eye lowering medication

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Feb 1994

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 1994

Completed
12.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

December 5, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 8, 2008

Completed
Last Updated

November 1, 2013

Status Verified

December 1, 2008

First QC Date

December 5, 2008

Last Update Submit

October 31, 2013

Conditions

Ocular HypertensionGlaucoma

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Qualifying IOP in at least one eye of each participant must be more than or equal 24 mmHg but less than or equal to 32 mm HG calculated from two separate consecutive determination taken at least 2 hours, but not greater than 12 weeks apart.
  • Normal and reliable 30-2 Humphrey Visual Fields in both eyes.
  • Normal Optic disc in both eyes on clinical examinations and stereoscopic photographs as determined by the Optic Disc Reading Center.

You may not qualify if:

  • Visual acuity worse than 20/40 in either eye on qualifying exam.
  • Previous intraocular surgery: laser trabeculoplasty, laser iridotomy, filtering surgery, combined cataract extraction/filtering procedures, penetrating keratoplasty and retinal detachment repair.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.

    PMID: 12049575BACKGROUND

MeSH Terms

Conditions

Ocular HypertensionGlaucoma

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Michael Kass, MD

    Washington University School of Medicine at St. Louis, St. Louis, Missouri

    STUDY CHAIR

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 5, 2008

First Posted

December 8, 2008

Study Start

February 1, 1994

Study Completion

December 1, 2006

Last Updated

November 1, 2013

Record last verified: 2008-12